EDAP Announces Final U.S. 2021 Reimbursement Rules for High Intensity Focused Ultrasound (HIFU)
EDAP Announces Final U.S. 2021 Reimbursement Rules for High Intensity Focused Ultrasound (HIFU)
- Final rules establish, for the first time, a Category 1 CPT code and reimbursement to physicians performing ablation of malignant prostate tissue with HIFU in the US
- Physician reimbursement for HIFU approximately 30% higher than cryotherapy and brachytherapy
- Hospital reimbursement for HIFU up approximately 6% versus 2020 levels
- Final reimbursement rule confirms proposed rule released on
August 12
On the Hospital Payment side, the final rule maintains the HIFU procedure in the Level 5 Urology Ambulatory Payment Classification (APC) in 2021. This translates into a payment for a hospital performing a HIFU procedure on a Medicare patient of around
In the Physician Fee Schedule final rule, CMS has established for the first time a payment to physicians performing a HIFU procedure in the US. In the final rule, CMS has set a total Relative Value Units (RVUs) for a physician performing a HIFU procedure at 29.09. This translates to an average payment of
About
A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device, as well as the length and severity of the recent COVID-19 outbreak, including its impacts across our businesses on demand for our devices and services. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the
Company Contact
Investor Relations / Legal Affairs
+33 4 72 15 31 50
bconfort@edap-tms.com
Investor Contact
212-915-2568
jeremy@lifesciadvisors.com
Source: EDAP TMS S.A.